These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19194969)

  • 21. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability of trans-resveratrol from red wine in humans.
    Vitaglione P; Sforza S; Galaverna G; Ghidini C; Caporaso N; Vescovi PP; Fogliano V; Marchelli R
    Mol Nutr Food Res; 2005 May; 49(5):495-504. PubMed ID: 15830336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects.
    la Porte C; Voduc N; Zhang G; Seguin I; Tardiff D; Singhal N; Cameron DW
    Clin Pharmacokinet; 2010 Jul; 49(7):449-54. PubMed ID: 20528005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid.
    Tzimas G; Nau H; Hendrickx AG; Peterson PE; Hummler H
    Teratology; 1996 Nov; 54(5):255-65. PubMed ID: 9035347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
    Adkison KK; Shachoy-Clark A; Fang L; Lou Y; O'Mara K; Berrey MM; Piscitelli SC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2802-6. PubMed ID: 15980352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High absorption but very low bioavailability of oral resveratrol in humans.
    Walle T; Hsieh F; DeLegge MH; Oatis JE; Walle UK
    Drug Metab Dispos; 2004 Dec; 32(12):1377-82. PubMed ID: 15333514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability.
    Lin HS; Ho PC
    J Pharm Sci; 2011 Oct; 100(10):4491-500. PubMed ID: 21520090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects.
    Nunes T; Almeida L; Rocha JF; Falcão A; Fernandes-Lopes C; Loureiro AI; Wright L; Vaz-da-Silva M; Soares-da-Silva P
    J Clin Pharmacol; 2009 Dec; 49(12):1477-82. PubMed ID: 19797536
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimization of trans-Resveratrol bioavailability for human therapy.
    Amiot MJ; Romier B; Dao TM; Fanciullino R; Ciccolini J; Burcelin R; Pechere L; Emond C; Savouret JF; Seree E
    Biochimie; 2013 Jun; 95(6):1233-8. PubMed ID: 23376875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Oral Bioavailability of Trans-Resveratrol from a Grapevine-Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization.
    Calvo-Castro LA; Schiborr C; David F; Ehrt H; Voggel J; Sus N; Behnam D; Bosy-Westphal A; Frank J
    Mol Nutr Food Res; 2018 May; 62(9):e1701057. PubMed ID: 29534330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, tissue distribution and excretion study of trans-resveratrol-3-O-glucoside and its two metabolites in rats.
    Su M; Dong C; Wan J; Zhou M
    Phytomedicine; 2019 May; 58():152882. PubMed ID: 30901659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic study of trans-resveratrol in adult pigs.
    Azorín-Ortuño M; Yañéz-Gascón MJ; Pallarés FJ; Vallejo F; Larrosa M; García-Conesa MT; Tomás-Barberán F; Espín JC
    J Agric Food Chem; 2010 Oct; 58(20):11165-71. PubMed ID: 20886884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats.
    Kapetanovic IM; Muzzio M; Huang Z; Thompson TN; McCormick DL
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):593-601. PubMed ID: 21116625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.
    Howells LM; Berry DP; Elliott PJ; Jacobson EW; Hoffmann E; Hegarty B; Brown K; Steward WP; Gescher AJ
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1419-25. PubMed ID: 21680702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of the resveratrol analogs trans-2,3-dimethoxy-stilbene and trans-3,4-dimethoxystilbene in rat plasma: application to pre-clinical pharmacokinetic studies.
    Ng SY; Cardullo N; Yeo SC; Spatafora C; Tringali C; Ong PS; Lin HS
    Molecules; 2014 Jul; 19(7):9577-90. PubMed ID: 25004068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats.
    Bertelli AA; Giovannini L; Stradi R; Urien S; Tillement JP; Bertelli A
    Int J Clin Pharmacol Res; 1996; 16(4-5):77-81. PubMed ID: 9172004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commentary on resveratrol and hormesis: resveratrol--a hormetic marvel in waiting?
    Marques FZ; Morris BJ
    Hum Exp Toxicol; 2010 Dec; 29(12):1026-8. PubMed ID: 21115564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration.
    Vitrac X; Desmoulière A; Brouillaud B; Krisa S; Deffieux G; Barthe N; Rosenbaum J; Mérillon JM
    Life Sci; 2003 Apr; 72(20):2219-33. PubMed ID: 12628442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.